HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients

Leukemia

Volumn 25, Issue 3, 2011, Pages 527-537

  Storti, P ^a   Donofrio, G ^a   Colla, S ^a,h   Airoldi, I ^b   Bolzoni, M ^a   Agnelli, L ^c   Abeltino, M ^a   Todoerti, K ^c   Lazzaretti, M ^a   Mancini, C ^a   Ribatti, D ^d   Bonomini, S ^a   Franceschi, V ^a   Pistoia, V ^b   Lisignoli, G ^e   Pedrazzini, A ^f   Cavicchi, O ^g   Neri, A ^c   Rizzoli, V ^a   Giuliani, N ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^f UNIVERSITY HOSPITAL OF PARMA   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

angiogenesis; HOXB7; microenvironment; multiple myeloma; transcription factors

Indexed keywords

SMALL INTERFERING RNA; THROMBOSPONDIN 2;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FGF2 GENE; GENE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC REGULATION; HOMEOBOXB 7 GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; MMP2 GENE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; NONOBESE DIABETIC MOUSE; NUCLEOTIDE SEQUENCE; PDGFA GENE; PRIORITY JOURNAL; SCID MOUSE; TRANSCRIPTION REGULATION; TUMOR VASCULARIZATION; UPREGULATION; VEGRA GENE; WNT5A GENE;

EID: 79952371298     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.270     Document Type: Article

References (44)

1. Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999; 93: 3064-3073. . (Pubitemid 29200799)
2. Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia 2006; 20: 193-199. . (Pubitemid 43148652)
3. Rajkumar SV, Leong T, Roche PC. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000; 6: 3111-3116. . (Pubitemid 30637735)
4. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002; 8: 2210-2216. . (Pubitemid 34753592)
5. Munshi NC, Wilson C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol 2001; 28: 565-569. . (Pubitemid 33134415)
6. Xu JL, Lai R, Kinoshita T, Nakashima N, Nagasaka T. Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. J Clin Pathol 2002; 55: 530-534. . (Pubitemid 34779306)
7. Alexandrakis MG, Passam FH, Dambaki C, Pappa CA, Stathopoulos EN. The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma. J Clin Pathol 2004; 57: 856-860. . (Pubitemid 39061436)
8. Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A et al. Induction of angiogenesis by normal and malignant plasma cells. Blood 2009; 114: 123-148. .
9. Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000; 95: 2630-2636. . (Pubitemid 30210543)
10. Podar K, Anderson KC. The pathophisiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005; 105: 1383-1395. . (Pubitemid 40223651)
11. Bisping G, Leo R, Wenning D, Dankbar B, Padró T, Kropff M et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 2003; 101: 2775-2783. . (Pubitemid 36857643)
12. Shapiro VS, Mollenauer MN, Weiss A. Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: implications for multiple myeloma progression. Blood 2001; 98: 187-193. .
13. Giuliani N, Colla S, Lazzaretti M, Sala R, Roti G, Mancini C et al. Pro-angiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 2003; 102: 638-645. . (Pubitemid 36841986)
14. Colla S, Morandi F, Lazzaretti M, Rizzato R, Lunghi P, Bonomini S et al. Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients. Leukemia 2005; 19: 2166-2176. . (Pubitemid 41741611)
15. Van Valckenborgh E, Croucher PI, De Raeve H, Carron C, De Leenheer E, Blacher S et al. Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model. Am J Pathol 2004; 165: 869-878. . (Pubitemid 39129294)
16. Barillé S, Akhoundi C, Collette M, Mellerin MP, Rapp MJ, Harousseau JL et al. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood 1997; 90: 1649-1655. . (Pubitemid 27355439)
17. Gorski DH, Walsh K. The role of homeobox genes in vascular remodeling and angiogenesis. Circ Res 2000; 87: 865-872. .
18. Carè A, Felicetti F, Meccia E, Bottero L, Parenza M, Stoppacciaro A et al. HOXB7: a key factor for tumor-associated angiogenic switch. Cancer Res 2001; 61: 6532-6539. . (Pubitemid 32783261)
19. Caré A, Silvani A, Meccia E, Mattia G, Peschle C, Colombo MP. Transduction of the SkBr3 breast carcinoma cell line with the HOXB7 gene induces bFGF expression, increases cell proliferation and reduces growth factor dependence. Oncogene 1998; 16: 3285-3289. . (Pubitemid 28330427)
20. Wu X, Chen H, Parker B, Rubin E, Zhu T, Lee JS et al. HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer Res 2006; 66: 9527-9534. . (Pubitemid 44623651)
21. Chen H, Lee JS, Liang X, Zhang H, Zhu T, Zhang Z et al. Hoxb7 inhibits transgenic HER-2/neu-induced mouse mammary tumor onset but promotes progression and lung metastasis. Cancer Res 2008; 68: 3637-3644. .
22. Caré A, Silvani A, Meccia E, Mattia G, Stoppacciaro A, Parmiani G et al. HOXB7 constitutively activates basic fibroblast growth factor in melanomas. Mol Cell Biol 1996; 16: 4842-4851. . (Pubitemid 26272139)
23. Giuliani N, Todoerti K, Lisignoli G, Tagliaferri S, Agnelli L, Morandi F et al. Gene expression profiling of isolated mesenchymal and osteoblastic cells exhibits a different pattern of expression in multiple myeloma patients as compared to healthy subjects: potential relationship with the presence of bone lesions. Blood 2007; 110: 3513a. .
24. Zufferey R, Nagy D, Mendel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875. .
25. Ribatti D, Nico B, Vacca A, Presta M. The gelatin spongechorioallantoic membrane assay. Nat Protoc 2006; 1: 85-91. .
26. Airoldi I, Di Carlo E, Banelli B, Moserle L, Cocco C, Pezzolo A et al. The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies. J Clin Invest 2004; 113: 1651-1959. .
27. Agnelli L, Mosca L, Fabris S, Lionetti M, Andronache A, Kwee I et al. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: An integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer 2009; 48: 603-614. .
28. Lombardi L, Poretti G, Mattioli M, Fabris S, Agnelli L, Bicciato S et al. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. Genes Chromosomes Cancer 2007; 46: 226-238. . (Pubitemid 46155318)
29. Giampaolo A, Pelosi E, Valtieri M, Montesoro E, Sterpetti P, Samoggia P et al. HOXB gene expression and function in differentiating purified hematopoietic progenitors. Stem Cells 1995; 13(Suppl 1): 90-105. .
30. Carè A, Valtieri M, Mattia G, Meccia E, Masella B, Luchetti L et al. Enforced expression of HOXB7 promotes hematopoietic stem cell proliferation and myeloid-restricted progenitor differentiation. Oncogene 1999; 18: 1993-2001. . (Pubitemid 29150086)
31. Shiraishi K, Yamasaki K, Nanba D, Inoue H, Hanakawa Y, Shirakata Y et al. Pre-B-cell leukemia transcription factor 1 is a major target of promyelocytic leukemia zinc-finger-mediated melanoma cell growth suppression. Oncogene 2007; 26: 339-348. . (Pubitemid 46122824)
32. Yamashita T, Tazawa S, Yawei Z, Katayama H, Kato Y, Nishiwaki K et al. Suppression of invasive characteristics by antisense introduction of overexpressed HOX genes in ovarian cancer cells. Int J Oncol 2006; 28: 931-938. .
33. Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 2007; 129: 879-890. . (Pubitemid 46813150)
34. Novak EM, Linardi C, Metzger M, Maria DA, Giorgi RR, Moura F et al. Differential expression of HOXB7 gene in multiple myeloma and extramedullary multiple myeloma patients. Eur J Haematol 2010; 84: 185-186. .
35. Risau W, Drexler H, Mironov V, Smits A, Siegbahn A, Funa K et al. Platelet-derived growth factor is angiogenic in vivo. Growth Factors 1992; 7: 261-266. . (Pubitemid 23079516)
36. de Fraipont F, Nicholson AC, Feige JJ, Van Meir EG. Thrombospondins and tumor angiogenesis. Trends Mol Med 2001; 7: 401-407. . (Pubitemid 32823989)
37. Rendtlew Danielsen JM, Knudsen LM, Dahl IM, Lodahl M, Rasmussen T. Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma. Br J Haematol 2007; 138: 756-760. . (Pubitemid 47313218)
38. Airoldi I, Cocco C, Giuliani N, Ferrarini M, Colla S, Ognio E et al. Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target. Blood 2008; 112: 750-759. .
39. Ling L, Nurcombe V, Cool SM. Wnt signaling controls the fate of mesenchymal stem cells. Gene 2009; 433: 1-7. .
40. Masckauchán TN, Agalliu D, Vorontchikhina M. Wnt5a signaling induces proliferation and survival of endothelial cells in vitro and expression of MMP-1 and Tie-2. Mol Biol Cell 2006; 17: 5163-5172. . (Pubitemid 44907359)
41. Huang CL, Liu D, Nakano J, Ishikawa S, Kontani K, Yokomise H et al. Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factorFan expression in non-small-cell lung cancer. J Clin Oncol 2005; 23: 8765-8773. . (Pubitemid 46211522)
42. O'Connell MP, Fiori JL, Xu M, Carter AD, Frank BP, Camilli TC et al. The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene 2009; 29: 34-44. .
43. Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J et al. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 2004; 10: 88-95. . (Pubitemid 38114166)
44. Milanović D, Maier P, Lohr F, Wenz F, Herskind C. Inhibition of 13-cis retinoic acid-induced gene expression of homeobox B7 by thalidomide. Int J Cancer 2007; 121: 1205-1211. (Pubitemid 47293786)